Pure large cell neuroendocrine carcinoma of the bladder without urological symptoms

Akdeniz, Ekrem; Bakırtaş, Mustafa; Bolat, Mustafa Suat; Akdeniz, Sevda; Özer, İsmail

doi:10.11604/pamj.2018.30.134.13437

Cited by 13 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical presentation of our patient was a typical presentation of bladder cancer, similar to the previously published cases, in which hematuria was a frequent presentation [ 3 – 5 , 7 , 8 , 12 , 13 , 17 – 19 ].…”

Section: Discussionsupporting

confidence: 89%

“…Less than forty cases of LCNC were reported so far in the literature. Only three cases had histological similarities to our case [ 3 – 5 ]. Management strategies are not yet studied prospectively [ 6 , 7 ].…”

Section: Introductionsupporting

confidence: 62%

“…The patient died 30 months after the surgery [ 9 ]. Subsequently, less than forty cases of pure and mixed LCNC were published [ 3 , 4 , 6 – 8 , 10 – 21 ]. To our knowledge, only three cases showed similar histological characteristics to our case, with LCNC and adenocarcinoma components [ 7 , 17 , 22 ].…”

Section: Discussionmentioning

confidence: 99%

“…A cisplatin-based chemotherapy consisted the base of the treatment strategies through literature. A multimodal therapeutic approach, using the combination of chemotherapy, radiotherapy, and radical or partial surgeries, has been reported [ 3 , 4 , 25 , 27 ]. Dowd et al reported after the treatment by surgical resection and adjuvant chemotherapy and radiotherapy, no recurrence at one year [ 4 ].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Large Cell Neuroendocrine Carcinoma of the Bladder with Adenocarcinomatous Component

Halabi

Abdessater

Boustany

et al. 2020

Case Reports in Urology

View full text Add to dashboard Cite

Large cell neuroendocrine carcinoma (LCNC) is one of the rarest types of bladder cancer occurring in <1%. Either pure or mixed with another component, it remains one of the most aggressive types of bladder cancer. We report a case of LCNC of the bladder with an adenocarcinomatous component. The patient was a 64-year-old smoker male, who presented for the first time with dysuria and hematuria. A bladder tumor invading the anterior and right lateral bladder walls was discovered, without any secondary localizations. Tumor biopsy showed an LCNC with adenocarcinomatous components. The patient was treated by recurrent tumor resections, chemotherapy, and radiotherapy. No improvement was noted despite close follow-up and adequate treatment. Neuroendocrine bladder tumor is known to have an aggressive, rapid, and disadvantageous evolution. Multiple case reports were published so far, and a recent review was conducted in March 2020 by Sanguedolce et al. (2020). More cases are needed to establish the best management plan for this type of tumor.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionsupporting

confidence: 62%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Large Cell Neuroendocrine Carcinoma of the Bladder with Adenocarcinomatous Component

Halabi

Abdessater

Boustany

et al. 2020

Case Reports in Urology

View full text Add to dashboard Cite

show abstract

“…In total, 25 publications ( 6 – 29 ) involving 38 cases were identified. The unreported case in our study was also included.…”

Section: Resultsmentioning

confidence: 99%

Clinical Characteristics, Treatment Strategy, and Outcomes of Primary Large Cell Neuroendocrine Carcinoma of the Bladder: A Case Report and Systematic Review of the Literature

et al. 2020

View full text Add to dashboard Cite

The aim of this study was to review the clinicopathologic characteristics, treatments, and outcomes of patients with primary large cell neuroendocrine carcinoma of the bladder (LCNEC). Patients and Methods: We report one patient diagnosed with primary pure LCNEC of the bladder in Sun Yat-sen Memorial Hospital. In addition, we performed a systematic literature review, in April 2020, on case report and case series of LCNEC of the bladder. The clinicopathologic characteristics, treatments and outcomes of this rare disease were analyzed. Results: A total of 39 patients were included in our analysis (1 case from our institution and 38 cases from the literature). Most patients (79.5%) were male. The average age at the surgery for the patients is 61.5 years (range 19-85 years). The most common symptom was hematuria (n = 20, 76.9%). Almost all patients (38, 97.4%) underwent surgery, with 26 (66.7%) receiving multimodality therapy. Out of 24 patients with available data, regional or distant recurrences developed in 14 patients (58.3%). The median overall survival of the patients was 11.5 months, with 1-and 3-year survival rates of 54.0 and 21.4%, respectively. In the survival analysis, theT1-2 tumors (P = 0.025), no distant metastases at diagnosis (P = 0.001), and multimodality therapy (P = 0.017) were associated with better overall survival (OS). Conclusions: LCNEC of the bladder is an extremely rare neoplasm. The available data suggest that the disease has an aggressive natural history with poor prognosis. Early pathologic stage and multimodality treatment may be important factors in determining prognosis.

show abstract

Neuroendocrine Tumors of the Urinary Bladder

Shehabeldin

2021

Urinary Bladder Pathology

View full text Add to dashboard Cite

Pure large cell neuroendocrine carcinoma of the bladder without urological symptoms

Cited by 13 publications

References 11 publications

Large Cell Neuroendocrine Carcinoma of the Bladder with Adenocarcinomatous Component

Large Cell Neuroendocrine Carcinoma of the Bladder with Adenocarcinomatous Component

Clinical Characteristics, Treatment Strategy, and Outcomes of Primary Large Cell Neuroendocrine Carcinoma of the Bladder: A Case Report and Systematic Review of the Literature

Neuroendocrine Tumors of the Urinary Bladder

Contact Info

Product

Resources

About